MediWound's EscharEx Phase III VALUE Study Recommended to Continue Without Modification

MediWound's EscharEx Phase III VALUE study to continue without modification after independent DSMB review, no safety concerns identified. The DSMB's recommendation is consistent with the favorable safety profile observed across the EscharEx clinical program. The company continues to expect the study's pre-specified interim sample-size reassessment and completion of patient enrollment by the end of the first quarter of 2027.